The Graeme Clark Oration - Australia's most prestigious free public science event

Science and Technology: New Frontiers for Helping People with Mental Illness

Thomas R. Insel, MD

Verily (Google Life Sciences), USA

MELBOURNE CONVENTION AND EXHIBITION CENTRE

TUESDAY 30 AUGUST 2016

See photos of event

Mental illnesses are amongst the most common, disabling, and costly disorders in all of medicine.  In contrast to most medical disorders, mental illnesses (including depression, anxiety disorders, schizophrenia, and bipolar disorder) usually begin before age 25.  This early onset combined with low rates of treatment too often incurs disability and high medical and social costs.  One recent report  estimated the annual cost of mental illness in Australia at over $28B per year, 2.2% of the nation’s GDP.  In addition to the disability and costs, these disorders are often fatal.  In Australia, suicide has increased to the highest rate in 13 years, with the recent report of 2,864 deaths/year or nearly one every 3 hours. Fortunately, science and technology offer hope for reducing the high morbidity and mortality of these disorders.

 

The revolutions in genomics and brain imaging have begun to reveal the fundamental biology of psychosis as well as mood and anxiety disorders, changing our perspective on these illnesses from exclusively behavioral problems to disorders of specific brain circuits.  Meanwhile new sensors and software that have revolutionized so many aspects of our lives have begun to offer better ways of measuring behavior, promising powerful tools for detecting early signs of psychosis or depression. Modern scientific and information technologies not only are suggesting more precise diagnostic boundaries that may help people get the right treatment at the right time, they are creating new approaches to treatment that may improve outcomes and prevent suicide.

 

This lecture will describe some of the recent advances in the science of mental illness and new frontiers in technology that give hope for reducing the suffering from serious mental illness.

 

 

Our 2016 Orator

Thomas R. lnsel, M.D., is a neuroscientist and psychiatrist, who joined Verily (formerly known as the Life Sciences Team at Google) in December, 2015. Previously he was Director of the National Institute of Mental Health (NIMH), the component of the U.S. National Institutes of Health (NIH) committed to research on mental disorders. Dr. Insel served as Director of this $1.5B agency from 2002 until 2015.

During his tenure, Dr. Insel focused on the genetics and neurobiology of mental disorders as well as transforming approaches to diagnosis and treatment. Prior to serving as NIMH Director, Dr. Insel was Professor of Psychiatry at Emory University where he was founding director of the Center for Behavioral Neuroscience and director of the Yerkes Regional Primate Center in Atlanta.

 

Dr. Insel’s research has examined the neural basis of complex social behaviors, including maternal care and attachment. A member of the National Academy of Medicine, he has received numerous national and international awards and served in several leadership roles at NIH, including as founding co-leader of both the NIH BRAIN Initiative and the NIH Neuroscience Blueprint and interim Director of the National Center for Accelerating Translational Sciences (NCATS).

 

 

View Tom Insel's Ted Talk on Mental Health

Blog

Why America’s Top Mental Health Researcher Joined Alphabet

 

Tom Insel explains why he’s ready to give Silicon Valley a try.

by Antonio Regalado  September 21, 2015 MIT Technology Review

 

One of Thomas Insel’s most dramatic initiatives as the government’s mental-health research czar was to try to throw out the psychiatrists’ bible, the Diagnostic and Statistical Manual of Mental Disorders, or DSM (see “NIMH Will Drop Widely Used Psychiatry Manual”).

 

It bothered Insel, who has been head of the National Institute of Mental Health in Bethesda, Maryland, since 2002, that unlike AIDS or lymphoma, mental illness is still diagnosed on the basis of clusters of symptoms rather than “any objective laboratory measure” such as a biomarker or readout.

 

In fact, biological science hasn’t had that many successes against depression or schizophrenia, despite the NIMH’s $1.5 billion a year in grants and research spending. Psychiatric drugs haven’t improved much in recent decades, and searches for the genetic causes of common forms of mental illness haven’t yielded clear answers either. Such scientific frustrations may explain why Insel last week said he was jumping ship to join a subsidiary of Alphabet, the tech conglomerate formed in the restructuring of Google. Alphabet’s Life Sciences unit is already exploring smart contact lenses, genomics, and cancer detection (see “A Deeper Look at the New Google”).

 

Insel notes the obvious: wealthy tech companies have realized that health care is a bigger business than software and gadgets (it’s about 20 percent of the U.S. GDP), and so it’s one they should get into. But he says he also became convinced that a tech approach might be well suited to mental illness, thanks to the “big data” being generated by genomics and medical imaging as well as the promise that personal technology could make health care “patient-centric” and continuous instead of focused on occasional doctor’s visits.

 

“In the future, when we think of the private sector and health research, we may be thinking of Apple and IBM more than Lilly and Pfizer,” Insel says. He’s not envisioning yet another app for managing diabetes or heart disease. Rather, he thinks smartphones could collect biomarkers of depression or psychosis via speech patterns, and dole out psychiatric interventions as well.

 

We spoke to Insel about his decision to head to Silicon Valley.

 

How were you recruited by Alphabet?

 

I was at a meeting with the person [Andy Conrad] who subsequently became the CEO of this new company. He is quite interested in doing something in mental health, but that is not his background. We were talking about opportunities and it became clear we had similar interests. He asked if I would like to do it at Alphabet rather than in government.

 

What interests did you have in common?

 

There are three areas of really clear shared interest. One is trying to figure out a better way to bring data analytics to psychiatry. The diagnostic system we have is entirely symptom based and fairly subjective. A second was a concern over how we approach psychosis—that we could move earlier in the chain to develop a preëmptive approach. And the third was autism and developing biomarkers [to diagnose it].

 

Those are all very much in the strategic plan of the NIH. It’s great to know that a company like Alphabet is also interested.

 

What would a pre-emptive approach to psychosis look like?

 

It’s something that we are also funding at the National Institute of Mental Health. We are developing algorithms to identify and analyse speech as an early window into the disorganization of thought.

 

Do you think you can do something different in Silicon Valley than in Bethesda, where you oversee such a large research enterprise?

 

We’ll see. I wouldn’t be making the move unless I thought there was a chance to have a greater impact from the private sector.

 

We are at a really interesting moment in time. Technology that already has had such a big impact, on entertainment and so many aspects of our lives, can really start to change health care. If you ask the question “What parts of health care can technology transform?”– mental health could be one of the biggest.

 

Technology can cover much of the diagnostic process because you can use sensors and collect information about behaviour in an objective way. Also, a lot of the treatments for mental health are psychosocial interventions, and those can be done through a smart phone. And most importantly, it can affect the quality of care, which is a big issue, especially for psychosocial interventions.

 

What do you mean by treating over the phone?

 

One of the best treatments for depression is cognitive behaviour therapy. It’s building a set of skills for managing your mood. You can do it with a phone as well as face to face. A lot of people with severe depression or social phobia or PTSD don’t want to go in to see someone. This lowers the bar.

 

Is it possible to diagnose mental illness with a phone?

 

I’d say you can collect information over the phone that can help people manage their own treatment. Your question rests on a paradigm that is completely shifting. The old paradigm is you go to the doctor and they write a prescription. Whether you call it a diagnosis or just identifying the issue, there is an awful lot that can be done online. There is an attachment for your smartphone than can see the tympanic membrane, and pediatricians can make a diagnosis [of ear infection] online. It’s a world where you want to get the right treatments at the right time for the right people. As a consumer, you are close to the source of the information. All of this is a different paradigm that we are moving into.

 

Is Alphabet’s approach to mental illness going to be primarily technological or biological?

 

I don’t know that. We are going to explore what the opportunities are. We know their sweet spot is in data analytics. What they do really well is figure out how to analyse data. The opportunity is to take that skill and answer biological questions. What that means in terms of what projects the life science team takes on in mental health is totally undefined. Part of my move there is to figure it out.

The Graeme Clark Oration

The Graeme Clark Oration is delivered by global leaders in health and medical science in honour of Prof. Graeme Clark’s pioneering work in developing the bionic ear in Melbourne in the 1970’s.  It is recognised as Australia’s most prestigious free public science event and is attended by secondary school students.